Can 'extrafine' dry powder aerosols improve lung deposition?

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 96, Issue , 2015, Pages 143-151

  De Boer, Anne H ^a   Gjaltema, Doetie ^a   Hagedoorn, Paul ^a   Frijlink, Henderik W ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Dry powder inhaler; Extrafine aerosol; ICS; Lung deposition; Small airway targeting; Submicron particles

Indexed keywords

BUDESONIDE PLUS FORMOTEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL XINAFOATE; AEROSOL; BRONCHODILATING AGENT; SALBUTAMOL;

AEROSOL; ARTICLE; BREATHING FREQUENCY MONITOR; DISPERSION; DRY POWDER; DRY POWDER INHALER; EXHALATION; FLOW RATE; HUMAN; IN VITRO STUDY; INHALATION; INHALER; LUNG CHARACTERISTICS AND FUNCTIONS; LUNG DEPOSITION; METERED DOSE INHALER; PARTICLE SIZE; AIRWAY RESISTANCE; ASTHMA; CHEMISTRY; DRUG EFFECTS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INHALATIONAL DRUG ADMINISTRATION; LUNG; METABOLISM; TISSUE DISTRIBUTION;

ADMINISTRATION, INHALATION; AEROSOLS; AIRWAY RESISTANCE; ALBUTEROL; ASTHMA; BRONCHODILATOR AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRY POWDER INHALERS; HUMANS; LUNG; PARTICLE SIZE; TISSUE DISTRIBUTION;

EID: 84938832656     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2015.07.016     Document Type: Article

References (38)

1. R.M. Angus Inhaled corticosteroids (budesonide): the cornerstone of asthma therapy - what are the options? Pulm. Pharmacol. Ther. 15 6 2002 479 484
2. A. Miller-Larsson, and O. Selroos Advances in asthma and COPD treatment: combination therapy with inhaled corticosteroids and long-acting beta 2-agonists Curr. Pharm. Des. 12 25 2006 3261 3279
3. M. Van den Berge, N.H. ten Hacken, J. Cohen, W.R. Douma, and D.S. Postma Small airway disease in asthma and COPD: clinical implications Chest 139 2 2011 412 423
4. O.S. Usmani, and P.J. Barnes Assessing and treating small airway disease in asthma and chronic obstructive pulmonary disease Ann. Med. 44 2 2012 146 156
5. N. Scichilone, M. Spatafora, S. Battaglia, R. Arrigo, A. Benfante, and V. Bellia Lung penetration and patient adherence considerations in the management of asthma: role of extra-fine formulations J. Asthma Allergy 6 2013 11 21
6. M. Corradi, H. Chrystyn, B.G. Cosio, M. Pirozynski, S. Loukides, R. Louis, M. Spinola, and O.S. Usmani NEXThaler, an innovative dry powder inhaler delivering an extrafine fixed combination of beclometasone and formoterol to treat large and small airways in asthma Exp. Opin. Drug Delivery 11 9 2014 1497 1506
7. C.L. Leach, P.J. Davidson, and R.J. Boudreau Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone Eur. Respir. J. 12 6 1998 1346 1353
8. H. Matthys, D. Nowak, S. Hader, and G. Kunkel Efficacy of chlofluorocarbon-free beclomethasone dipropionate 400 micrograms day-1 delivered as an extrafine aerosol in adults with moderate asthma Respir. Med. 92 Suppl. A 1998 17 22
9. G. Gross, P.J. Thompson, P. Chervinsky, and J. Vanden Burgt Hydrofluoroalkane-134a beclomethasone dipropionate, 400 microg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 microg, for the treatment of moderate asthma Chest 115 2 1999 343 351
10. H. Chrystyn, and D. Price Not all asthma inhalers are the same: factors to consider when prescribing an inhaler Prim. Care Respir. J. 18 4 2009 243 249
11. T.W. de Vries, B.L. Rottier, D. Gjaltema, P. Hagedoorn, H.W. Frijlink, and A.H. de Boer Comparative in vitro evaluation of four corticosteroid metered dose inhalers: consistency of delivered dose and particle size distribution Respir. Med. 103 2009 1167 1173
12. F. Lavorini, G.A. Fontana, and O.S. Usmani New inhaler devices - the good, the bad and the ugly Respiration 88 1 2014 3 15
13. O.S. Usmani Small-airway disease in asthma: pharmacological considerations Curr. Opin. Pulm. Med. 21 2015 55 67
14. O.S. Usmani Small airways dysfunction in asthma: evaluation and management to improve asthma control Allergy Asthma Immunol. Res. 5 2014 376 388
15. C.L. Leach Improved delivery of inhaled steroids to the large and small airways Respir. Med. 92 Suppl. A 1998 3 8
16. Chiesi, Fostair NEXThaler Summary of Product Characteristics 〈https://www.medicines.org.uk/emc/medicine/29177〉 (Accessed January 2015).
17. J. Heyder, J. Gebhart, G. Rudolf, C.F. Schiller, and W. Stahlhofen Deposition of particles in the human respiratory tract in the size range 0.005-15 μm J. Aerosol Sci. 17 5 1986 811 825
18. G. Rudolf, J. Gebhart, J. Heyder, Ch.F. Schiller, and W. Stahlhofen An empirical formula describing aerosol deposition in man for any particle size J. Aerosol Sci. 17 3 1986 350 355
19. N. Khajeh-Hosseini-Dalasm, and P.W. Longest Deposition of particles in the alveolar airways: inhalation and breath-hold with pharmaceutical aerosols J. Aerosol Sci. 79 2015 15 30
20. W.C. Hinds Aerosol technology Properties, Behavior, and Measurement of Airborne Particles 1982 John Wiley & Sons Inc. New York (Chapter 3, pp. 38-50 and Chapter 11, pp. 211-232)
21. B.J. Gabrio, S.W. Stein, and D.J. Velasquez A new method to evaluate plume characteristics of hydrofluoroalkane and chlorofluorocarbon metered dose inhalers Int. J. Pharm. 186 1 1999 3 12
22. P. Demoly, P. Hagedoorn, A.H. de Boer, and H.W. Frijlink The clinical relevance of dry powder inhaler performance for drug delivery Respir. Med. 108 2014 1195 1203
23. F. Lavorini, A. Magnan, J.C. Dubus, T. Voshaar, L. Corbetta, M. Broeders, R. Dekhuijzen, J. Sanchi, J.L. Viejo, P. Barnes, C. Corrigan, M. Levy, and G.K. Crompton Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD Respir. Med. 102 2008 593 604
24. O.S. Usmani, M.F. Biddiscombe, and P.J. Barnes Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size Am. J. Respir. Crit. Care Med. 172 12 2005 1497 1504
25. A.R. Clark, and A.M. Hollingworth The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers - implications for in-vitro testing J. Aerosol Med. 6 1992 99 110
26. A.H. de Boer, H.M.I. Winter, and C.F. Lerk Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers Part 1. Inhalation characteristics, work of breathing and volunteers' preference in dependence of the inhaler resistance Int. J. Pharm. 130 1996 231 244
27. United States Pharmacopoeia, Aerosols, metered dose inhalers and dry powder inhalers, USP30-NF25 2007.
28. J.P. Mitchell Practices of coating collection surfaces of cascade impactors: a survey of members of the European Pharmaceutical Aerosol Group (EPAG) Drug Delivery Lungs 14 2003 75 78
29. P.E. Morrow, and C.P. Yu Models of aerosol behaviour in airways F. Morén, M.T. Newhouse, M.B. Dolovich, Aerosols in Medicine. Principles, Diagnosis and Therapy 1985 Elsevier Sci. Publishers, Biomedical Division Amsterdam 149 191
30. T.R. Gerrity Pathophysiological and disease constraints on aerosol delivery P.R. Byron, Respiratory Drug Delivery 1990 CRC Press Boca Raton 1 38
31. T.B. Martonen, and I.M. Katz Deposition patterns of aerosolized drugs within the human lungs: effects of ventilatory parameters Pharm. Res. 10 6 1993 871 878
32. M. Hindle, and P.W. Longest Evaluation of enhanced condensational growth (ECG) for controlled respiratory drug delivery in a mouth-throat and upper tracheobronchial model Pharm. Res. 27 2010 1800 1811
33. Y-J. Son, P.W. Longest, and M. Hindle Aerosolization characteristics of dry powder inhaler formulations for the excipient enhanced growth (EEG) application: effect of spray drying process conditions on aerosol performance Int. J. Pharm. 443 2013 137 145
34. G. Tian, P.W. Longest, X. Li, and M. Hindle Targeting aerosol deposition to and within the lung airways using excipient enhanced growth J. Aerosol Med. Pulm. Drug Deliv. 26 2013 248 265
35. W.H. DeHaan, and W.H. Finlay Predicting extrathoracic deposition from dry powder inhalers Aerosol Sci. 35 2004 309 331
36. P. Begat, D.A. Morton, J. Schur, P. Kippax, J.N. Straniforth, and R. Price The role of force control agents in high-dose dry powder inhaler formulations J. Pharm. Sci. 98 8 2009 2270 2783
37. B.L. Laube, H.M. Janssens, F.H. de Jongh, S.G. Davadason, R. Dhand, P. Diot, M.L. Everard, I. Horvath, P. Navalesi, T. Voshaar, and H. Chrystyn What the pulmonary specialist should know about the new inhalation therapies Eur. Respir. J. 37 6 2011 1308 1331
38. S.P. Newman How well do in vitro particle size measurements predict lung delivery in vivo? J. Aerosol Med. 11 Suppl. 1 1998 S97 S104